Santiago González Santiago
Hospital San Pedro de Alcántara(ES)
Publications by Year
Research Areas
BRCA gene mutations in cancer, HER2/EGFR in Cancer Research, PARP inhibition in cancer therapy, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology
Most-Cited Works
- → Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial(2019)194 cited
- → Uso de paneles de genes en pacientes con alto riesgo de cáncer digestivo hereditario: documento de posicionamiento de la AEG, SEOM, AEGH y consorcio IMPaCT-GENÓMICA(2023)7 cited
- → A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).(2018)6 cited
- → Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.(2024)4 cited
- → Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).(2023)2 cited
- → Abstract OT1-12-09: Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)(2022)1 cited
- → Longitudinal clinical, physiological and molecular profiling of female metastatic cancer patients: protocol and feasibility of a multicenter high-definition oncology study(2025)1 cited
- → Use of multi-gene panels in patients at high risk of hereditary digestive cancer: Position statement of AEG, SEOM, AEGH and IMPaCT-GENÓMICA consortium(2024)1 cited
- → ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation (BRCAm) testing and counselling model for patients with ovarian cancer.(2017)
- → A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples(2025)